{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:27:38Z","timestamp":1783078058941,"version":"3.54.6"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K16327"],"award-info":[{"award-number":["22K16327"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018254","name":"The Japanese Foundation For Research and Promotion of Endoscopy","doi-asserted-by":"publisher","award":["22K08482"],"award-info":[{"award-number":["22K08482"]}],"id":[{"id":"10.13039\/100018254","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejphar.2026.178922","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T14:41:16Z","timestamp":1777732876000},"page":"178922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Elotuzumab enhances the anti-tumor activity of V\u03b39V\u03b42\u00a0T cells against primary effusion lymphoma"],"prefix":"10.1016","volume":"1025","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9151-4972","authenticated-orcid":false,"given":"Kosuke","family":"Maeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusho","family":"Kariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutatip","family":"Panaampon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3124-5206","authenticated-orcid":false,"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178922_bib1","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.exphem.2009.04.008","article-title":"Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma","volume":"37","author":"Abe","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejphar.2026.178922_bib2","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2004-01-0331","article-title":"FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways","volume":"104","author":"Angelini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178922_bib3","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","article-title":"Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein","volume":"123","author":"Bachanova","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178922_bib4","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00262-008-0491-8","article-title":"Phase-I study of innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma","volume":"57","author":"Bennouna","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejphar.2026.178922_bib5","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00262-010-0879-0","article-title":"Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumors","volume":"59","author":"Bennouna","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejphar.2026.178922_bib6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1126\/science.1110267","article-title":"Professional antigen-presentation function by human gammadelta T cells","volume":"309","author":"Brandes","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2026.178922_bib7","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.4049\/jimmunol.1301889","article-title":"CD56(bright)perforin(low) noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph","volume":"192","author":"Carrega","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2026.178922_bib8","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","article-title":"Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-Related body-cavity-based lymphomas","volume":"332","author":"Cesarman","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.178922_bib9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nature22076","article-title":"SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin","volume":"544","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.178922_bib10","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejphar.2026.178922_bib11","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1182\/blood-2011-06-363655","article-title":"Antibody-dependent anti-cytomegalovirus activity of human gammadelta T cells expressing CD16 (FcgammaRIIIa)","volume":"119","author":"Couzi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178922_bib12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.intimp.2014.07.036","article-title":"Ex vivo-expanded natural killer cells kill cancer cells more effectively than ex vivo-expanded gammadelta T cells or alphabeta T cells","volume":"22","author":"Deng","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2026.178922_bib13","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting human gammadelta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer","volume":"67","author":"Dieli","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.178922_bib14","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ni.1763","article-title":"Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells","volume":"10","author":"Dong","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejphar.2026.178922_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030729","article-title":"Human peripheral blood gamma Delta T cells: report on a series of healthy caucasian Portuguese adults and comprehensive review of the literature","volume":"9","author":"Fonseca","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2026.178922_bib16","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00262-017-2011-1","article-title":"Zoledronic acid renders human M1 and M2 macrophages susceptible to Vdelta2(+) gammadelta T cell cytotoxicity in a perforin-dependent manner","volume":"66","author":"Fowler","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejphar.2026.178922_bib17","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.4049\/jimmunol.168.10.4920","article-title":"Patterns of chemokine receptor expression on peripheral blood gamma delta T lymphocytes: strong expression of CCR5 is a selective feature of V delta 2\/V gamma 9 gamma delta T cells","volume":"168","author":"Glatzel","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2026.178922_bib18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s12185-013-1339-3","article-title":"Establishment of a CD4-positive cell line from an AIDS-related primary effusion lymphoma","volume":"97","author":"Goto","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ejphar.2026.178922_bib19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1128\/MCB.01107-14","article-title":"Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells","volume":"35","author":"Guo","year":"2015","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2026.178922_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-2815-6_2","article-title":"Measurement of the T cell response to preerythrocytic vaccination in mice","volume":"1325","author":"Guthmiller","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejphar.2026.178922_bib21","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2012-05-430470","article-title":"Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human gammadelta T-cell subset","volume":"120","author":"Harly","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178922_bib22","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s00262-022-03165-w","article-title":"Tafasitamab mediates killing of B-cell non-hodgkin's lymphoma in combination with gammadelta T cell or allogeneic NK cell therapy","volume":"71","author":"Her","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejphar.2026.178922_bib23","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3389\/fimmu.2018.00800","article-title":"Improving the efficiency of Vgamma9Vdelta2 T-Cell immunotherapy in cancer","volume":"9","author":"Hoeres","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.178922_bib24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1006\/viro.2002.1759","article-title":"Phenotypic analysis of peripheral blood gammadelta T lymphocytes and their targeting by human immunodeficiency virus type 1 in vivo","volume":"305","author":"Imlach","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.ejphar.2026.178922_bib25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jcyt.2012.12.004","article-title":"Ex vivo characterization of gammadelta T-cell repertoire in patients after adoptive transfer of Vgamma9Vdelta2 T cells expressing the interleukin-2 receptor beta-chain and the common gamma-chain","volume":"15","author":"Izumi","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ejphar.2026.178922_bib26","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00262-011-1021-7","article-title":"Phase I\/II study of adoptive transfer of gammadelta T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma","volume":"60","author":"Kobayashi","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejphar.2026.178922_bib27","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00262-006-0199-6","article-title":"Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study","volume":"56","author":"Kobayashi","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejphar.2026.178922_bib28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s00066-019-01434-9","article-title":"Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study","volume":"195","author":"Kokowski","year":"2019","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/j.ejphar.2026.178922_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/CJI.0b013e318245bb1e","article-title":"Tumor-promoting versus tumor-antagonizing roles of gammadelta T cells in cancer immunotherapy: results from a prospective phase I\/II trial","volume":"35","author":"Kunzmann","year":"2012","journal-title":"J. Immunother."},{"key":"10.1016\/j.ejphar.2026.178922_bib30","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1158\/1535-7163.MCT-17-0998","article-title":"Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab","volume":"17","author":"Kurdi","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejphar.2026.178922_bib31","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.4049\/jimmunol.166.12.7190","article-title":"Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen","volume":"166","author":"Lafont","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2026.178922_bib32","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00262-011-1049-8","article-title":"Pilot trial of interleukin-2 and zoledronic acid to augment gammadelta T cells as treatment for patients with refractory renal cell carcinoma","volume":"60","author":"Lang","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejphar.2026.178922_bib33","article-title":"Human gammadelta T cell subsets and their clinical applications for cancer immunotherapy","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejphar.2026.178922_bib34","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1182\/blood-2011-05-356535","article-title":"HIV envelope-mediated, CCR5\/alpha4beta7-dependent killing of CD4-negative gammadelta T cells which are lost during progression to AIDS","volume":"118","author":"Li","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178922_bib35","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ejphar.2026.178922_bib36","first-page":"11 11","article-title":"Flow cytometric analysis of cell division by dilution of CFSE and related dyes","volume":"9","author":"Lyons","year":"2013","journal-title":"Curr Protoc Cytom Chapter"},{"key":"10.1016\/j.ejphar.2026.178922_bib37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/ni.3327","article-title":"Tolerance is established in polyclonal CD4(+) T cells by distinct mechanisms, according to self-peptide expression patterns","volume":"17","author":"Malhotra","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejphar.2026.178922_bib38","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2016.00262","article-title":"Human circulating and tissue-resident CD56(bright) natural killer cell populations","volume":"7","author":"Melsen","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.178922_bib39","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2249.2010.04167.x","article-title":"In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients","volume":"161","author":"Meraviglia","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejphar.2026.178922_bib40","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00018-011-0706-6","article-title":"Gammadelta T-APCs: a novel tool for immunotherapy?","volume":"68","author":"Moser","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejphar.2026.178922_bib41","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V88.2.645.bloodjournal882645","article-title":"Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus","volume":"88","author":"Nador","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178922_bib42","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.ejcts.2009.11.051","article-title":"A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells","volume":"37","author":"Nakajima","year":"2010","journal-title":"Eur. J. Cardio. Thorac. Surg."},{"key":"10.1016\/j.ejphar.2026.178922_bib43","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/bjc.2011.293","article-title":"Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours","volume":"105","author":"Nicol","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.178922_bib44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/14653249.2010.515581","article-title":"Zoledronate-activated Vgamma9gammadelta T cell-based immunotherapy is feasible and restores the impairment of gammadelta T cells in patients with solid tumors","volume":"13","author":"Noguchi","year":"2011","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ejphar.2026.178922_bib45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5582\/irdr.2014.01010","article-title":"Current status of treatment for primary effusion lymphoma","volume":"3","author":"Okada","year":"2014","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.ejphar.2026.178922_bib46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/cam4.178","article-title":"Classification of AIDS-related lymphoma cases between 1987 and 2012 in Japan based on the WHO classification of lymphomas, fourth edition","volume":"3","author":"Ota","year":"2014","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejphar.2026.178922_bib47","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00262-022-03177-6","article-title":"Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells","volume":"71","author":"Panaampon","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejphar.2026.178922_bib48","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1084\/jem.171.5.1597","article-title":"Evidence for extrathymic changes in the T cell receptor gamma\/delta repertoire","volume":"171","author":"Parker","year":"1990","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2026.178922_bib49","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1339853","article-title":"The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms","volume":"6","author":"Pazina","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejphar.2026.178922_bib50","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3389\/fimmu.2018.00984","article-title":"Human gammadelta T-Cells: from surface receptors to the therapy of high-risk leukemias","volume":"9","author":"Pistoia","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.178922_bib51","article-title":"In vivo expansion and activation of gammadelta T cells as immunotherapy for refractory neuroblastoma: a phase 1 study","volume":"95","author":"Pressey","year":"2016","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.ejphar.2026.178922_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1080","article-title":"Gammadelta T cells in cancer: a small population of lymphocytes with big implications","volume":"8","author":"Raverdeau","year":"2019","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.ejphar.2026.178922_bib53","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/CJI.0b013e318207ecfb","article-title":"Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gammadeltaTcells: a phase I clinical study","volume":"34","author":"Sakamoto","year":"2011","journal-title":"J. Immunother."},{"key":"10.1016\/j.ejphar.2026.178922_bib54","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.7150\/thno.25149","article-title":"Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors","volume":"8","author":"Sanchez-Martinez","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2026.178922_bib55","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.immuni.2014.03.003","article-title":"The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vgamma9Vdelta2 T cells","volume":"40","author":"Sandstrom","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2026.178922_bib56","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nri3904","article-title":"Gammadelta T cells in cancer","volume":"15","author":"Silva-Santos","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2026.178922_bib57","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2003.06.013","article-title":"Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study","volume":"21","author":"Simonelli","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.178922_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005201","article-title":"Peripheral Vgamma9Vdelta2 T cells are a novel reservoir of latent HIV infection","volume":"11","author":"Soriano-Sarabia","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejphar.2026.178922_bib59","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jcyt.2016.04.001","article-title":"Bioengineering and serum free expansion of blood-derived gammadelta T cells","volume":"18","author":"Sutton","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ejphar.2026.178922_bib60","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178922_bib61","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1002\/ijc.23365","article-title":"V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab","volume":"122","author":"Tokuyama","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.178922_bib62","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2002-12-3665","article-title":"Gammadelta T cells for immune therapy of patients with lymphoid malignancies","volume":"102","author":"Wilhelm","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.178922_bib63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1479-5876-12-45","article-title":"Successful adoptive transfer and in vivo expansion of haploidentical gammadelta T cells","volume":"12","author":"Wilhelm","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejphar.2026.178922_bib64","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.immuni.2019.02.016","article-title":"A structural change in butyrophilin upon phosphoantigen binding underlies phosphoantigen-mediated Vgamma9Vdelta2 T cell activation","volume":"50","author":"Yang","year":"2019","journal-title":"Immunity"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926004048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926004048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:09:52Z","timestamp":1783076992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926004048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":64,"alternative-id":["S0014299926004048"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178922","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elotuzumab enhances the anti-tumor activity of V\u03b39V\u03b42\u00a0T cells against primary effusion lymphoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178922","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178922"}}